Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

BDX

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

BDX

AI Research Report

Powered by Claude

Ready to analyze BDX

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

📅 Earnings in 22d (May 7)
  • Yahoo·9h ago

    Becton Dickinson (BDX) Q2 2025 Earnings Transcript

    Tom Polen: Thank you, Greg, and good morning, everyone. My comments this morning will focus on our Q2 results and the strategic actions we are taking to not only navigate the near-term environment with agility, but to ensure BD is best positioned to deliver long-term value.

  • Yahoo·9h ago

    Becton Dickinson (BDX) Q3 2025 Earnings Transcript

    At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at (800) 839-1246 for domestic calls and area code +1 402 220-0464 for international calls. Thank you for joining us.

  • Benzinga·4d ago

    Goldman Sachs Reinstates Neutral on Becton Dickinson, Announces $167 Price Target

    Goldman Sachs analyst David Roman reinstates Becton Dickinson (NYSE:BDX) with a Neutral and announces $167 price target.

  • Yahoo·4d ago

    Nike downgraded, IBM initiated: Wall Street's top analyst calls

    Nike downgraded, IBM initiated: Wall Street's top analyst calls

  • Yahoo·4d ago

    Becton Dickinson Trials Highlight Growth Potential In Interventional And Home Care

    Becton Dickinson (NYSE:BDX) advanced its Liverty TIPS Stent Graft for portal hypertension toward EU approval, supported by pivotal clinical data to be presented at a major scientific meeting. The company reported positive clinical results for its PureWick Urine Collection System, reinforcing comfort and efficacy for non invasive management of urinary incontinence. These developments highlight product innovation and clinical evidence in liver disease care and urinary incontinence that expand...

  • Yahoo·4d ago

    Market Crash: The Healthcare Stocks I'd Buy Without Hesitation

    Don't miss out on these opportunities.

  • Yahoo·5d ago

    BD to Announce Financial Results for its Second Quarter of Fiscal 2026

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, May 7, 2026 to discuss the Company's financial results for its second quarter of fiscal year 2026, which ended on March 31, 2026, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available sh

  • Yahoo·5d ago

    Rick Byrd to Retire from BD

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Richard (Rick) Byrd has informed the company of his intent to retire after nearly 25 years with BD.

  • View all news →
Becton Dickinson and Co

Becton Dickinson and Co

Health Care·NEW YORK STOCK EXCHANGE, INC.·US·IPO 1963-09-25

Analyst Consensus

Buy
Based on 20 analysts
Period: 2026-04-01
9 Buy (45%)11 Hold (55%)0 Sell (0%)
Rating Distribution
Strong Buy
5
Buy
4
Hold
11
Sell
0
Strong Sell
0
Trend
2026-04
9/11/0
2026-03
9/11/0
2026-02
7/11/0
2026-01
7/11/0

Recent insider activity

View all →
  • 4FORM 4
    9d ago
  • 4FORM 4
    19d ago
  • 4FORM 4
    29d ago
  • 4FORM 4
    Mar 4
  • 4FORM 4
    Mar 4
NEW YORK STOCK EXCHANGE, INC.Market closed
Becton Dickinson and Co
Health Care
$155.73
$0.30 (+0.19%)
Open
$155.02
Prev close
$155.43
Day range
$154.40 – $156.18
52W range
$127.54 – $187.35
Mkt cap
$44.34B
P/E
25.2
EPS
$6.12
Beta
0.28

Fundamentals

Valuation
Market Cap
$44.34B
P/E (TTM)
25.23S&P avg ~22
P/S (TTM)
2.02S&P avg ~2.8
P/B
2.19S&P avg ~4.5
P/FCF
16.85S&P avg ~26
EPS (TTM)
$6.12
Book/sh
$88.79
Cash/sh
$2.64
Profitability
Gross Margin
46.42%avg ~45%
Operating Margin
12.15%avg ~15%
Net Margin
8.01%avg ~12%
ROE
6.93%avg ~18%
ROA
3.20%avg ~7%
ROI
3.93%
Payout Ratio
67.90%
FCF/sh
—
Growth & Health
Rev Growth YoY
6.22%
Rev Growth 5Y
6.32%
EPS Growth YoY
1.63%
EPS Growth 5Y
13.42%
Current Ratio
—
Quick Ratio
0.40
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.28
52W High
$187.35
52W Low
$127.54
Avg Vol (10D)
2.26M
Avg Vol (3M)
2.38M
Div Yield
2.70%
Div/sh (TTM)
—
Analyst
Buy (20)
Price Performance
5D+0.30%
MTD-1.14%
3M-3.60%
6M+3.02%
YTD+1.91%
1Y-0.67%

Factor Grades

View details →
C
Overall score: 52/100
B-
Valuation
C+
Growth
C+
Profitability
D+
Momentum
C-
Financial Health